Literature DB >> 19365663

Amino-terminal pro-B-type natriuretic peptide in refractory Kawasaki disease.

Fernando Maria de Benedictis1, Massimo Colaneri, Patrizia Osimani, Maria Grazia Bettuzzi.   

Abstract

Serum concentrations of brain natriuretic peptide and its amino-terminal cleavage pro-fragment, NT-proBNP, have never been reported in refractory Kawasaki disease. Changes in NT-proBNP levels after infliximab treatment in an infant with severe cardiovascular complications are reported here. The regular evaluation of this cardiac biomarker after infliximab treatment may have clinical relevance in patients with refractory Kawasaki disease and severe heart involvement.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19365663     DOI： 10.1007/s00246-009-9416-3

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN： 0172-0643            Impact factor:   1.655


  12 in total

1.  Home monitoring anticoagulation therapy in infants.

Authors:  F M de Benedictis; B Lattanzi; M Colaneri
Journal:  Arch Dis Child       Date:  2008-08       Impact factor: 3.791

2.  Plasma brain natriuretic peptide concentrations in patients with Kawasaki disease.

Authors:  T Kawamura; M Wago; H Kawaguchi; M Tahara; M Yuge
Journal:  Pediatr Int       Date:  2000-06       Impact factor: 1.524

3.  Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease.

Authors:  S Kurotobi; N Kawakami; K Shimizu; H Aoki; S Nasuno; K Takahashi; S Kogaki; K Ozono
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

4.  Does Abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease?

Authors:  Richard V Williams; Venus M Wilke; Lloyd Y Tani; L LuAnn Minich
Journal:  Pediatrics       Date:  2002-01       Impact factor: 7.124

5.  Infliximab treatment for refractory Kawasaki syndrome.

Authors:  Jane C Burns; Wilbert H Mason; Sarmistha B Hauger; Hillel Janai; John F Bastian; Julie D Wohrley; Ian Balfour; Cynthia A Shen; Edward D Michel; Stanford T Shulman; Marian E Melish
Journal:  J Pediatr       Date:  2005-05       Impact factor: 4.406

6.  Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements.

Authors:  Brian W McCrindle; Jennifer S Li; L LuAnn Minich; Steven D Colan; Andrew M Atz; Masato Takahashi; Victoria L Vetter; Welton M Gersony; Paul D Mitchell; Jane W Newburger
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

7.  Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase.

Authors:  Kenneth K Ma; Tsuneo Ogawa; Adolfo J de Bold
Journal:  J Mol Cell Cardiol       Date:  2004-04       Impact factor: 5.000

8.  Incomplete and atypical Kawasaki disease in a young infant: severe, recalcitrant disease responsive to infliximab.

Authors:  Matthew J O'connor; Frank T Saulsbury
Journal:  Clin Pediatr (Phila)       Date:  2007-05       Impact factor: 1.168

9.  Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm.

Authors:  Taku Oishi; Mikiya Fujieda; Taisuke Shiraishi; Miki Ono; Kazuo Inoue; Akiyoshi Takahashi; Hideo Ogura; Hiroshi Wakiguchi
Journal:  Circ J       Date:  2008-05       Impact factor: 2.993

Review 10.  Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients.

Authors:  Martin Christopher Johns; Carol Stephenson
Journal:  Am J Cardiol       Date:  2008-02-04       Impact factor: 2.778
View more
  1 in total

1.  Cardiovascular biomarkers in acute Kawasaki disease.

Authors:  Yuichiro Z Sato; Delaram P Molkara; Lori B Daniels; Adriana H Tremoulet; Chisato Shimizu; John T Kanegaye; Brookie M Best; James V Snider; Jeffrey R Frazer; Alan Maisel; Jane C Burns
Journal:  Int J Cardiol       Date:  2011-07-20       Impact factor: 4.164
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.